STOCK TITAN

BridgeBio Pharma CEO Neil Kumar receives 71,216 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) reported that CEO Neil Kumar received 71,216 common shares when RSUs vested on November 16, 2026. 36,236 shares were withheld for taxes at $77.36 per share. The four RSU tranches vest quarterly after their initial vesting dates, subject to continued service. The report lists indirect holdings of 495,686 shares in Kumar Haldea Family Irrevocable Trust, 750,000 shares in NK 2026 GRAT and 3,568,447 shares in Kumar Haldea Revocable Trust; Kumar disclaims beneficial ownership except to the extent of any pecuniary interest.
Insider Kumar Neil
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Restricted Stock Units F1, F5 33,544 $0.00 $0.00
Exercise Restricted Stock Units F1, F6 19,599 $0.00 $0.00
Exercise Restricted Stock Units F1, F7 11,554 $0.00 $0.00
Exercise Restricted Stock Units F1, F8 6,519 $0.00 $0.00
Exercise Common Stock F1 33,544 -- --
Exercise Common Stock F1 19,599 -- --
Exercise Common Stock F1 11,554 -- --
Exercise Common Stock F1 6,519 -- --
Tax Withholding Common Stock F2 36,236 $77.36 $2.80M
Holding Common Stock F3 -- -- --
Holding Common Stock F4 -- -- --
Holding Common Stock F3 -- -- --
Holdings After Transaction: Restricted Stock Units — 320,280 units (Direct); Common Stock — 278,307 shares (Direct); Common Stock — 495,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 750,000 shares (Indirect, By NK 2026 GRAT); Common Stock — 3,568,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes (8)
  1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. F2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,216 shares of Common Stock underlying the Reporting Person's RSUs.
  3. F3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  4. F4. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
  5. F5. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
  6. F6. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
  7. F7. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
  8. F8. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
RSUs vested 71,216 shares November 16, 2026; the units represented contingent rights to receive common shares
Shares withheld for taxes 36,236 shares November 16, 2026; withheld to satisfy the tax obligation related to RSU vesting
Withholding price $77.36 per share November 16, 2026; shares withheld to satisfy the tax obligation
Kumar Haldea Family Irrevocable Trust holdings 495,686 shares Indirect common-stock holdings reported November 16, 2026
NK 2026 GRAT holdings 750,000 shares Indirect common-stock holdings reported November 16, 2026
Kumar Haldea Revocable Trust holdings 3,568,447 shares Indirect common-stock holdings reported November 16, 2026
Restricted Stock Unit financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
grantor retained annuity trust technical
"the NK 2026 GRAT, a grantor retained annuity trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
pecuniary interest financial
"except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did BridgeBio CEO Neil Kumar receive from RSUs?

Neil Kumar received 71,216 common shares when RSUs vested on November 16, 2026.

How many BBIO shares were withheld for taxes from Neil Kumar’s RSU vesting?

36,236 shares were withheld to satisfy his tax obligation, at $77.36 per share.

What are the vesting terms for Neil Kumar’s BBIO RSUs?

The RSUs vested as to 1/16th of the underlying shares on each award’s initial date: May 16, 2023, May 16, 2024, May 16, 2025, or May 16, 2026, respectively. Thereafter, 1/16th vests quarterly, subject to continued service with BridgeBio or a subsidiary. The RSUs have no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Neil

(Last)(First)(Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M33,544A(1)276,871D
Common Stock11/16/2026M19,599A(1)296,470D
Common Stock11/16/2026M11,554A(1)308,024D
Common Stock11/16/2026M6,519A(1)314,543D
Common Stock11/16/2026F36,236(2)D$77.36278,307D
Common Stock495,686IBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock750,000IBy NK 2026 GRAT(4)
Common Stock3,568,447IBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)11/16/2026M33,544 (5) (5)Common Stock33,544$033,544D
Restricted Stock Units(1)11/16/2026M19,599 (6) (6)Common Stock19,599$097,997D
Restricted Stock Units(1)11/16/2026M11,554 (7) (7)Common Stock11,554$0103,984D
Restricted Stock Units(1)11/16/2026M6,519 (8) (8)Common Stock6,519$084,755D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,216 shares of Common Stock underlying the Reporting Person's RSUs.
3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
4. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
5. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
6. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
7. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
8. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Remarks:
/s/ Will Solis, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading